SCIESCOPUSQ2
Therapeutic Advances in Hematology
SAGE PUBLICATIONS LTD, United Kingdom
Therapeutic Advances in Hematology is an academic journal published by SAGE PUBLICATIONS LTD (United Kingdom). Identifiers: ISSN 2040-6207, eISSN 2040-6215. Indexed in SCIE, SCOPUS. Metrics: JIF 3.1, CiteScore 5.2, SJR 1.180, SNIP 0.96. Subject areas: HEMATOLOGY. tlooto lists 752 papers from this journal.
CiteScore
5.20
Scopus citation metric
SJR
1.180
SCImago rank
SNIP
0.96
Source normalized impact
Percentage rank
-
JIF percentile rank
Journal profile
- ISSN
- 2040-6207
- eISSN
- 2040-6215
- Abbreviation
- THER ADV HEMATOL
- Publisher
- SAGE PUBLICATIONS LTD
- Country
- United Kingdom
Web of Science categories
SCIEHEMATOLOGY
Scopus ASJC categories
2720 Hematology
Keywords
Hematology
Papers in this journal
Recent papers
- Clinical practice of the endothelial activation and stress index and its modified versions in multiple myeloma and the effects on prognosis
2026 · 1 citations
- Real-world efficacy and tolerability of ixazomib-based combination therapies in advanced multiple myeloma and other plasma cell neoplasms
2026
- Real-world study of use patterns and clinical outcomes for patients with myelodysplastic syndrome initiating oral decitabine and cedazuridine or intravenous/subcutaneous hypomethylating agents.
2026
- Ruxolitinib treatment in patients with polycythemia vera reduces JAK2 variant allele frequency and improves symptom burden and hematocrit control
2026
- Efficacy and safety of Busulfan–Fludarabine versus Busulfan–Cyclophosphamide as a conditioning regimen prior to hematopoietic stem cell transplant in hematologic malignancy patients: a meta-analysis of randomized controlled trials and observational studies
2026
Most cited papers
- Myeloid sarcoma: current approach and therapeutic options
2011 · 265 citations
- Factor VIII inhibitors in hemophilia A: rationale and latest evidence
2013 · 217 citations
- CAR T-cell therapy for B-cell lymphomas: clinical trial results of available products
2019 · 198 citations
- Treatment and management of graft-versus-host disease: improving response and survival
2013 · 182 citations
- The evolving role of FLT3 inhibitors in acute myeloid leukemia: quizartinib and beyond
2014 · 171 citations